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Abstract
Spinal muscular atrophy (SMA) is a recessive autosomal neuromuscular disease, due to homozygous mutations or
deletions in the telomeric survival motoneuron gene 1 (SMN1). SMA is characterized by motor impairment, muscle
atrophy, and premature death following motor neuron (MN) degeneration. Emerging evidence suggests that
dysregulation of autophagy contributes to MN degeneration. We here investigated the role of autophagy in the
SMNdelta7 mouse model of SMA II (intermediate form of the disease) which leads to motor impairment by postnatal
day 5 (P5) and to death by P13. We first showed by immunoblots that Beclin 1 and LC3-II expression levels increased in
the lumbar spinal cord of the SMA pups. Electron microscopy and immunofluorescence studies confirmed that
autophagic markers were enhanced in the ventral horn of SMA pups. To clarify the role of autophagy, we administered
intracerebroventricularly (at P3) either an autophagy inhibitor (3-methyladenine, 3-MA), or an autophagy inducer
(rapamycin) in SMA pups. Motor behavior was assessed daily with different tests: tail suspension, righting reflex, and
hindlimb suspension tests. 3-MA significantly improved motor performance, extended the lifespan, and delayed MN
death in lumbar spinal cord (10372.36 ± 2716 MNs) compared to control-group (5148.38 ± 94 MNs). Inhibition of
autophagy by 3-MA suppressed autophagosome formation, reduced the apoptotic activation (cleaved caspase-3 and
Bcl2) and the appearance of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive neurons,
underlining that apoptosis and autophagy pathways are intricately intertwined. Therefore, autophagy is likely involved
in MN death in SMA II, suggesting that it might represent a promising target for delaying the progression of SMA in
humans as well.
Introduction
Spinal muscular atrophy (SMA) is an autosomal reces-
sive neurodegenerative disease selectively affecting
motoneurons (MNs) in the spinal cord. SMA symptoms
include motor impairment, muscle weakness, and atrophy
that lead at the death of infants and toddlers1. SMA is
caused by inactivation of the evolutionarily highly con-
served survival motoneuron 1 (SMN1) telomeric gene and
subsequent reduction of the full length SMN1 (FL-SMN1)
protein, which results in the loss of lower MNs. SMN1
plays an important role in the maturation of splicing small
nuclear ribonucleoproteins2. Humans display a second
centromeric copy of the gene, SMN2, bearing a C to T
transition in exon 7. This mutation leads to the lack of
exon 7 during transcription and encodes a truncated, less-
functional protein, SMNdelta73–5. Wirth et al.6 demon-
strated that the increase in the copy number of SMN2
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attenuates the symptom severity and delays the age of
onset. The low amount of FL-SMN protein in combina-
tion with the instability of SMNdelta7 triggers the
pathological condition in SMA patients7. Despite the
genetic cause of SMA is unequivocal, the molecular
mechanisms that lead to selective motor neuron (MN)
loss and clinical symptoms remain controversial. In order
to perform preclinical studies to understand the patho-
genesis and to test new therapeutic targets, several
in vitro8 and in vivo9 models have been generated
reproducing the hallmarks of the disease. The SMNdelta7
SMA mouse is the most widely used and best-
characterized model of SMA (SMN2+/+; SMNdelta7+/+;
Smn−/−) with a lifespan of about 13 days10. It represents
an intermediate SMA form (SMA type II), recapitulating
several features of the human disease: behaviorally, for the
early motor symptoms and, morphologically, for the
degeneration of lower MNs.
Abnormal autophagy has garnered attention as a sig-
nificant contributor to neurodegeneration11. In eukar-
yotes, autophagy is a physiological process that
contributes to various events, such as intracellular
cleansing leading to the degradation of long-lived pro-
teins, cytoplasmic organelles, and toxic agents, as by
fusion with pre-existing lysosomes12. Autophagy consists
of several sequential steps: (i) the formation of autopha-
gosomes which are typically labeled by the microtubule-
associated protein 1A/1B-light chain 3 (LC3)13–15, (ii)
fusion with the lysosomes, and (iii) degradation of the
cargo by lysosomal hydrolases16.
A recent report described the increase of autophagic
vesicles in SMN-depleted MN cultures and in MNs cul-
tured from SMA mice, suggesting an increase of autop-
hagosomes without impairment of the autophagic flux17.
On the contrary, Custer and Androphy18 observed an
impairment of the autophagic degradative pathway in cell
culture and animal models of SMA. Therefore, autophagy
dysregulation can represent a new pathogenetic hypoth-
esis in SMA and its pharmacological manipulation could
influence the progression of the disease.
Several studies showed that autophagy is intimately
intertwined to apoptosis, and same regulators can some-
times control both. In SMAI patients, the relevance of
apoptosis has been underscored by several authors. Simic
et al.19 showed apoptosis is involved in MN degeneration.
Soler-Botija et al.20 demonstrated a decrease in the levels
of Bcl2 and a delay in the expression of Bcl-X in post-
mortem spinal cords from SMAI foetuses at 15 weeks in
comparison with controls. Furthermore, Tsai et al.21
found that overexpression of anti-apoptotic Bcl-xL
extended the lifespan in a mouse model of SMA. With its
dual role in life and death, autophagy assumes a pivotal
position in various physiological events such as develop-
ment and aging, and in many pathological conditions.
Our findings underscore a significant role of autophagy in
SMA: its manipulation by 3-methyladenine (3-MA, an auto-
phagic inhibitor) delayed MN degeneration and increased
lifespan in the SMNdelta7 mouse model, thus providing a
possible therapeutic target in the treatment of SMA.
Results
Increased expression of autophagic and apoptotic markers
in the lumbar spinal cord of SMA pups
In order to investigate whether autophagy is specifically
implicated in the MN degeneration in SMA mouse model,
we analyzed the lumbar spinal cord by western blot (WB)
analysis. Beclin 1 protein levels were significantly higher
in SMA (1.70± 0.004 SD) than in the control (1.37±
0.004 SD, ***p< 0.001) (Fig. 1a, b). Moreover, LC3-II
protein levels increased significantly in SMA pups (0.24±
0.0086 SD) compared to the control (0.09± 0.0003 SD,
***p< 0.001) (Fig. 1a, b). Moreover, immunoreactivity for
LC3 was strikingly higher in lumbar spinal cord of SMA
pups compared to the control (Fig. 1c). High magnifica-
tion showed a large number of LC3-positive dots in the
ventral horns of SMA pups (Fig. 1d). LC3-positive dots
counts showed a significant increase in the number of
autophagosomes per cell in SMA (27.34± 1.64 SD) in
comparison to the controls (3.42± 0.98 SD, ***p< 0.001)
(Fig. 1e). Double-immunostaining showed accumulation
(see figure on previous page)
Fig. 1 Autophagic markers increase in the spinal cord of SMA pups. a Representative WB of Beclin 1 and LC3 in the lumbar spinal cord extracts
from control (WT) and SMA pups. b Beclin 1 and LC3-II levels quantified by densitometry and normalized to β-actin of three independent
experiments. Asterisks indicate significant differences using one-way ANOVA test and Bonferroni post-hoc multiple comparisons (***p < 0.001). c
Immunohistochemical analysis of LC3 (red) in the lumbar spinal cord (ventral horn) at P9 in control (WT) and SMA pups. Nuclei are stained with DAPI
(blue). LC3-positive dots are rarely observed in control samples (WT) whereas strong immunoreactivity for LC3 is detected in the spinal cord of SMA
pups. d High magnification representative image showing increased LC3-positive puncta in the cytoplasm of SMA pups. e Graph, showing the
corresponding quantification of LC3-positive puncta per cell, indicated as mean value ± SD from WT and SMA pups (***p < 0.001). f High
magnification representative image of LC3-positive puncta (red) in SMI32-positive MN (green). DAPI (blue) in merge picture. Scale bars: 10 µm.
g, h Protein extracts of lumbar spinal cords in WT (control) and SMA with anti-p62/SQSTM1 antibody by WB analysis. Graph values represent the
expression of p62/SQSTM1 normalized with β-actin and correspond to the quantification of three independent experiments. No statistic differences
were found between control and SMA groups by one-way analysis of variance (ANOVA), followed by post-hoc Bonferroni test (not significant, n.s.).
i, j Quantitative analysis of repeated WB analysis against cleaved caspase-3 and Bcl2 in SMA in comparison to the WT (***p < 0.001). Scale bars: 100
µm c and 5 µm d
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of LC3-positive dots in SMI32-labeled MNs in the ventral
spinal cords of SMA pups (Fig. 1f).
The increase of autophagosomes could not necessarily
indicate an increase in autophagosome biogenesis, but
might also be due to a defect in the autophagic flux. In
order to discern between these two hypotheses, we mea-
sured the protein level of p62/SQSTM1, which is selec-
tively degraded by autophagy22. p62/SQSTM1 were
unchanged in SMA (0.48± 0.024 SD) compared to the
control (0.43± 0.018 SD, not significant), suggesting that
the autophagic flux is unaffected (Fig. 1g, h).
To further investigate the mechanisms of MN cell death
in SMA, we assessed the levels of the apoptotic markers,
cleaved caspase-3 and Bcl2 in the lumbar spinal cord in
SMA and control group. WB analyses showed a remark-
able increase in cleaved caspase-3 expression in SMA
pups (0.39± 0.008 SD) (vs. control 0.075 ± 0.001 SD, ***p
< 0.001) (Fig. 1i, j) and Bcl2 levels were reduced in SMA
(0.19± 0.001 SD) (vs. control 0.55 ± 0.004 SD, ***p<
0.001) (Fig. 1i, j). Therefore, these results suggested also
the occurrence of the apoptotic process in SMA.
Presence of autophagic features in dying lower MNs of
SMA pups, assessed by electron microscopy
In order to confirm the involvement of autophagy in
dying MNs in the SMA model, we performed ultra-
structural analysis on the ventral horns of lumbar spinal
cords in P5 and P10 mice. Whereas at P5 electron
microscopy analysis did not reveal any increase of
autophagy and cell death feature in the soma of MNs (not
shown), at P10 the cytoplasm of MNs showed marked
alterations and signs of cellular disruption. Indeed, most
MN cell bodies displayed ultrastructural abnormalities:
shrinkage and vacuolization of cytoplasm, swelling of the
endoplasmic reticulum and the perinuclear membrane,
convoluted nuclei associated with few chromatin
condensation and increased autophagic features (autop-
hagosomes and autolysosomes; Fig. 2).
3-MA treatment prevents the increase in autophagy
occurring in SMA
To further explore the role of autophagy in the
pathogenesis of SMA disease, we performed the intra-
cerebroventricular (ICV) administration of 3-MA, a
common autophagy inhibitor, at P3 (SMA-3MA group),
and we evaluated if the modulation of autophagy could
influence the disease progression. Quantification ana-
lyses indicated that Beclin 1 was reduced in SMA after 3-
MA administration in comparison to the control (SMA-
saline, 1.47 ± 0.02 SD; SMA-3MA, 1.10 ± 0.004 SD, ***p
< 0.001) (Fig. 3a, b). Also LC3-II protein levels were
significantly decreased in SMA pups after 3-MA
administration (SMA-saline, 0.61 ± 0.008 SD; SMA-
3MA, 0.18 ± 0.009 SD, ***p < 0.001) (Fig. 3a, b). Immu-
nostaining against LC3 showed a relevant reduction in
SMA-3MA group compared with SMA-saline pups
(Fig. 3c). LC3-positive puncta counts showed a sig-
nificant reduction in the number of autophagic vesicles
per cell after 3-MA treatment (5.15 ± 0.93 SD) in com-
parison to SMA-saline group (27.5 ± 4.51 SD) (Fig. 3d,
**p < 0.01). Moreover, Beclin 1 immunoreactivity was
strongly reduced after 3-MA treatment in comparison
with vehicle group (Fig. 3e). After 3-MA administration,
p62/SQSTM1 protein level was significantly increased
(SMA-3MA 0.64 ± 0.026 SD; ***p < 0.001) in comparison
to the control groups (SMA-saline 0.40 ± 0.06 SD),
suggesting a reduction of autophagy activity (Fig. 3f, g).
Altogether, these results suggested an inhibition of the
autophagy pathway in the lumbar spinal cord after the
ICV administration of 3-MA.
To determine whether changes in SMN after 3-MA
treatment can be detected in isolated MNs from an in vivo
Fig. 2 Increased autophagic features in MN in the ventral horn of lumbar spinal cord of SMA pups in comparison to control group. a
Representative electron micrograph of motoneuron cell body in P10 WT mice. High magnifications showed the mitochondria (m), the endoplasmic
reticulum (ER) and the Golgi apparatus (GA). b, c Representative electron micrographs of motoneuron cell body in P10 SMA mice (N: nucleus). High
magnifications revealed the presence of both autophagosomes (*) and autolysosomes (#) in the cytoplasm of SMA motoneurons. Dying
motoneurons displayed cytoplasmic shrinkage, increased autophagic features (autophagosomes and autolysosomes), swelling of ER and perinuclear
membrane and convoluted nuclei with few chromatin condensation (see in c). Scale bar: 1 µm
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SMA model, we used the Smn−/−;SMN2+/+ (mutSMA)
mouse. We dissected and genotyped E13 embryos by
crossing two Smn+/−;SMN2+/+ mutants. LC3-II protein
was increased in mutSMA cultures compared with WT
control cells (1.69± 0.12, p< 0.05, data not shown).
However, LC3-II levels were reduced in WT and
mutSMA 3-MA-treated cells (0.69± 0.08, *p< 0.05 and
0.65± 0.04, ***p< 0.001, respectively) compared with
Fig. 3 (See legend on next page.)
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non-treated conditions (SF. 1a). Additionally, Smn protein
level was increased in both WT and mutSMA 3-MA-
treated conditions (1.34± 0.12- and 1.74± 0.31-fold
increase, *p< 0.05, respectively) compared with non-
treated controls (SF. 1b). We measured p62/SQSTM1 in
WT and mutSMA conditions and we observed significant
increase in mutSMA (2.12± 0.31-fold increase, p< 0.05,
data not shown) compared with WT control. 3-MA
treatment increased p62/SQSTM1 in WT-treated cells
(1.35± 0.08-fold induction, **p< 0.005) compared with
non-treated cells, but no significant differences in p62/
SQSTM1 level were observed in 3-MA-treated and non-
treated mutSMA conditions (SF. 1c).
Autophagy manipulation modulates MN degeneration in
SMA mice
To evaluate how autophagy manipulation can influence
MN death, we performed stereological counts of MNs in
Nissl-stained sections (Fig. 4). The analyses were per-
formed on lumbar spinal cords of P9 WT and SMA pups
treated with vehicle (SMA-saline) and 3-MA (SMA-3MA)
or rapamycin (SMA-RAP). The number of MNs was
greatly decreased in SMA-saline (5148.38± 94 SD MNs/
lumbar spinal cord) and SMA-RAP groups (5864.16±
1042.81 SD) compared to WT (12706.13± 2068 SD,
respectively p= 0.002 and p= 0.005, **); however, the
SMA-3MA group showed a significantly increased number
of MNs (10372.36± 2716 SD) when compared to SMA-
saline and SMA-RAP (respectively p= 0.02 and p< 0.05,
*), and a not significant difference compared to WT
(Fig. 4b). These results suggest that 3-MA treatment delays
MN degeneration in the lumbar spinal cord of SMA pups.
Relationship between autophagy and apoptosis
We analyzed the protein levels of cleaved caspase-3 and
Bcl2 in the lumbar spinal cord after 3-MA administration.
WB analyses showed a remarkable reduction of cleaved
caspase-3 in SMA-3MA mice (0.25± 0.0044 SD, ***p<
0.001) in comparison to SMA-saline (0.34± 0.008)
(Fig. 5a, b). In addition, Bcl2 levels were increased (SMA-
3MA, 0.77± 0.008 SD, ***p< 0.001) compared to the
SMA-saline group (0.48± 0.002 SD) (Fig. 5a, b). Immu-
nohistochemical analysis showed that cleaved caspase-3
was absent in SMA pups after 3-MA treatment, whereas
some positive cells could be detected in SMA-saline
(Fig. 5c and insert 5c'). Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL)-staining
gave similar results (Fig. 5d and insert 5d'). Taken toge-
ther, our results showed that the 3-MA administration
reduced cell death, underlying the relationship between
autophagy and apoptosis in the control of MN degen-
eration in the spinal cord of SMA mice.
Modulation of autophagy affects the survival of SMA mice
We found that 3-MA administration slightly, but sig-
nificantly, increased the lifespan of SMA pups (N= 10,
15.4 vs. 13.21 days; p= 0.025; Fig. 6). On the contrary,
SMA-RAP (N= 10) pups showed a significant reduction
of lifespan compared with SMA-saline (N= 14, *p=
0.014) and SMA-3MA (***p= 0.001).
Autophagy involvement in disease progression in SMA
mice
In order to evaluate the effects of modulating autophagy
in the progression of disease, body weight, and a battery of
behavioral tests were performed daily. All mice were
observed from P2 to the killing (P9), and subdivided in
four SMA groups: saline-treated (SMA-SAL, N= 3), 3-
MA-treated (SMA-3MA, N= 5–14), rapamycin-treated
(SMA-RAP, N= 3–13), and D3-MA-treated (double
administration of 3-MA at P3 and P6, N= 3–6) (SMA-
D3MA) (Fig. 7).
Body weight
No significant differences were found among the four
groups (Fig. 7a).
Tail suspension test
This test measures motor coordination in pups. The
performance before the treatment was overlapping among
(see figure on previous page)
Fig. 3 Decrease in autophagic markers and activity in the lumbar spinal cord of SMA after ICV administration of 3-MA. a Protein extracts of
spinal cord of control (WT) and SMA pups with anti-Beclin 1, LC3 and β-actin by WB analysis. b Graphs values represent the expression of Beclin 1 and
LC3-II normalized with β-actin in SMA pups treated with vehicle (saline) and 3-MA. Results correspond to three independent experiments ±SD.
Asterisks indicate significant differences determined by one-way ANOVA, followed by post-hoc Bonferroni test (***p < 0.001). c
Immunohistochemistry staining using an antibody against LC3 (red) and nuclear staining (DAPI, blue) in SMA treated with vehicle (SMA-saline) and
3-MA (SMA-3MA). Scale bar: 100 µm. d Graphs represent the mean of LC3-positive puncta per cell, corresponding to the quantification of three
independent experiments ±SD in SMA treated with saline and 3-MA. Asterisk indicates significant difference using one-way ANOVA followed by post-
hoc Tukey test (**p < 0.01). e Immunostaining of lumbar spinal cord in SMA treated with vehicle (SMA-saline) and 3-MA (SMA-3MA) against Beclin 1
(red) (DAPI, blue). Scale bar: 100 µm (20 µm, high magnification). f WB analysis of p62/SQSTM1 in SMA treated with saline or 3-MA. g Protein levels of
p62/SQSTM1 by densitometry and normalized to β-actin. Results are shown as the mean value ± SD (mean of three independent experiments).
Asterisks indicate significant differences by one-way ANOVA test, followed by post-hoc Bonferroni test (***p < 0.001)
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the groups. After 3-MA treatment, pups showed a better
performance in comparison to the SMA-SAL and SMA-
RAP groups, but the positive results were transient.
Therefore, we created a group of SMA pups with a double
administration of 3-MA (P3 and P6), which showed a
strong improvement in motor behavioral test to P3 from
P9 (Fig. 7b).
Righting reflex test
This simple assay was performed to evaluate motor
coordination. The SMA-SAL and SMA-RAP pups failed
the test. When 3-MA was administrated at P3, pups
recovered their righting reflex. At P4 and P5, SMA-3MA
pups had improved (P4: 14.53 ± 2.99 SEM; P5: 15.18±
2.84 SEM) in comparison to SMA-SAL (P4: 30, *p=
0.033; P5: 30, *p= 0.012) and SMA-RAP (P4: 28± 2 SEM,
**p= 0.003; P5: 27.92± 1.15 SEM, ***p= 0.001). How-
ever, 3 days after the administration (P6), the SMA-3MA
(24.75± 1.97 SEM) pups progressively lost their capability
and performed similarly to SMA-SAL (30) and SMA-RAP
pups (29± 1 SEM). These results showed a transient
positive effect of 3-MA. SMA pups following double
administration of 3-MA, the improvement was consistent
and lasted from P3 to P9 (P6: 7.6± 3.19 SEM; P7: 11.87±
5.77 SEM; P8= 3.33± 0.33 SEM; P9: 9.57± 5.95 SEM,
***p< 0.001) (Fig. 7c).
Fig. 4 Effects of autophagy inhibition on MN survival. a Example of an SMA P9 lumbar spinal cord three-dimensional reconstruction by
StereoInvestigator software. Schematic dorsal view (left) and transverse section (right) of the lumbar spinal cord show the localization of the MNs (red
dots) in the ventral part (red volume). The white matter is in cyan and gray matter in yellow. b Graph and table indicate the number of MNs
(stereological counts) in the lumbar spinal cord (ventral horn) at P9 in WT, SMA-saline, SMA-3MA, and SMA-Rapamycin (SMA-RAP) groups. Statistical
difference between the groups are indicated (*p < 0.05; **p < 0.01)
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Hindlimb suspension test
This test evaluates hindlimb strength and coordination.
SMA-D3MA pups improved motor performance, in
absence of differences among other groups (Fig. 7d).
All these data suggest that autophagy inhibition might
reduce the disease progression in SMA model.
Discussion
Autophagy is an evolutionarily conserved mechanism
across eukaryotes which removes damaged organelles and
protein aggregates from the cytoplasm. The essential steps
of autophagy involve several autophagy-related (ATG)
proteins15,23. Throughout their life, neurons are particu-
larly dependent on autophagy to maintain their home-
ostasis and neuron-specific knockout for Atg5 or
Atg7 showed axonal degeneration and neuron death in
mice24–27. However, autophagy is considered a Janus-faced
mechanism, which can alternatively either protect from or
contribute to neuronal damage: for example, the accumu-
lation of autophagic vesicles has been reported in human
post-mortem brains of patients affected by neurodegen-
erative disorders28,29 and in mouse models of neurode-
generation30–32. Autophagy has been suggested as a
fundamental process whose dysregulation can be also
Fig. 5 Administration of 3-MA reduces apoptotic cell death in the lumbar spinal cord of SMA. a Protein extraction of lumbar spinal cord from
different groups. b Quantitative analysis of repeated WB analysis against cleaved caspase-3 and Bcl2. After 3-MA administration, results indicate
reduction of cleaved caspase-3 protein level in SMA in comparison to SMA-saline group (a, b). Quantitative analysis of repeated WB shows increased
level of Bcl2 after 3-MA administration (a, b). c Staining shows the presence of cleaved caspase-3-positive cells (c and high magnification c', red) and
TUNEL-positive cells (d and high magnification d', green) in the ventral horn in the lumbar spinal cord of SMA-saline but absence of positive cells in
SMA-3MA group. Nuclear staining (DAPI, blue). Scale bar: 50 m (5 μm, insert)
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involved in neurodegenerative diseases and become, finally,
a potential target for therapy. A dysregulation of autophagy
has been reported in SMA: Garcera et al.17 provided the
first evidence, reporting an increased number of autopha-
gic features in cultured CD1 mouse model after lentiviral
short hairpin RNA Smn-reduction. Periyakaruppiah33
revealed an increase of autophagic vesicles in Smn-reduced
spinal cord MNs from a murine model of severe SMA,
suggesting that autophagy is dysregulated. Moreover,
Custer and Androphy18 observed the presence of autop-
hagic vesicles in an inducible NSC-34 cell culture model of
SMA, in fibroblasts isolated from SMA patients and in
spinal cord extracts of “Taiwanese” mouse model of SMA.
According to these results, a recent report described an
increase of mRNA expression level of autophagy markers
in the spinal cord of a severe mouse model of SMA34.
Our results in the delta7 in vivo model are in agreement
with these previous reports. We observed increased Beclin
Fig. 6 Effect of 3-MA on the lifespan in the SMA pups. a The results of Kaplan−Meier survival analysis indicate the probability of survival in the
vehicle-, 3-MA- and rapamycin-treated SMA pups. b The significant difference between the groups
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1 and LC3-II protein levels in the lumbar spinal cord of
the SMA mouse model. In addition, immunofluorescence
staining and electron microscopy results showed an
increased number of autophagic vesicles in the lumbar
MNs in SMA mice.
Autophagosomes might accumulate when autophago-
somal digestion is impaired. Therefore, we checked the
level of p62/SQSTM1, a marker of autophagic flux22.
Previous in vitro studies using SMN-depleted cells18,33
demonstrated increased p62/SQSTM1 protein levels
suggesting a decreased autophagic flux. Custer and
Androphy18 reported similar results in a severe mouse
model of SMA. On the contrary, in our intermediate
mouse model of SMA, the p62/SQSTM1 protein levels
were unchanged in the spinal cord compared to the
control group. Therefore, in our mouse model, autophagy
was upregulated, but the autophagic flux was unaffected.
In support of this hypothesis, Garcera et al. suggested a
Fig. 7 Body weight and behavioral tests in SMA pups. Analysis of body weight and motor behavior (from P2 to P9) of SMA treated with saline
(blue line), rapamycin (green) and single (P3, red) or double (P3 and P6, purple) administration of 3-MA. The grams, score, and the seconds are
expressed as mean±SD. Statistical difference between the groups are indicated (*p < 0.05; **p < 0.01; ***p < 0.001) (not significant, n.s.)
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normal autophagic flux in an in vitro model of SMA17
showing increased LC3-II level after Bafilomycin
treatment.
Several studies suggested that autophagosome accu-
mulation may interfere with intracellular trafficking and/
or may become a source of cytotoxic products35,36. In
order to understand whether reduction of autophago-
somes could improve the pathogenesis of the disease, we
treated the SMA pups with 3-MA, an autophagy inhibitor.
The levels of Beclin 1 and LC3-II decreased in the lumbar
spinal cord of SMA mice following ICV administration of
3-MA and the number of LC3-positive vesicles reduced in
3-MA-treated SMA pups. In accordance with these data,
the p62/SQSTM1 protein levels increased after 3-MA
administration. These data demonstrated that 3-MA
suppressed autophagosome formation and autophagy
activity in the lumbar spinal cords of SMA mouse model.
Then, we performed stereological MN counts in the
lumbar spinal cord and we measured the lifespan and
motor function of the animals. Our study showed that 3-
MA delayed MN degeneration and improved motor
behavior temporarily and slightly but significantly
increased the lifespan, confirming the relevance of
autophagy in SMA neurodegeneration and suggesting for
the first time that modulation of autophagy by 3-MA may
affect disease progression. The relevance of modulating
autophagy through 3-MA is further highlighted by the
results we obtained in vitro, where it increased SMN
protein levels both in WT and in mutSMA cultured MNs.
This corroborates the hypothesis of a strong relationship
between autophagy and SMN, completely aimed at sup-
porting/maintaining the healthy MN state. In support of
our observation, Olivan et al.34 also described the neu-
roprotective effects, due by the reduction of autophagy
markers and pro-apoptotic gene using a non-viral gene
therapy in a mouse model of SMA.
Furthermore, we investigated the link between autop-
hagy and apoptosis. According to previous studies in the
spinal cord of children with the severe form of SMA19 and
in mouse models of SMA20,21, we observed increased
cleaved caspase-3 and reduced Bcl2 protein levels com-
pared to the control. Interestingly, 3-MA treatment
reduced apoptotic cell death in the lumbar spinal cord,
underlining the important relationship between autop-
hagy and apoptosis, as already suggested by several
authors32,37–39. Inhibitors of autophagy can trigger40 or
inactivate apoptosis41 depending on the context. Several
authors demonstrated that Bcl2 family members inhibit
autophagy by linking Beclin 137. Altogether, these results
suggest that Beclin 1-dependent autophagy is modulated
in our experimental SMA model and could determine
MN degeneration.
However, autophagy in MN diseases plays a con-
troversial role, as reviewed recently42. For example, in
amyotrophic lateral sclerosis (ALS), the survival of MNs is
affected by impaired autophagy43. Impairment of the
retrograde axonal transport in SOD1 G93A mice may be
responsible for the accumulation of autophagosomes as a
result of a defect in the autophagosome−lysosome fusion,
which occurs mainly in the soma44. Despite several lines
of evidence highlighting the role of autophagy in ALS
pathogenesis45, knocking-out MN autophagy proved to be
insufficient to replicate ALS in mice46. Nevertheless, it has
been shown that in ALS aggregated misfolded proteins,
such as TDP-43 and SOD1, may form and accumulate in
MN soma and axons47,48, thus activating autophagy49.
The inhibition of autophagy by 3-MA may induce
aggregates containing TDP-4350. On the contrary, the
inhibition of mTOR using rapamycin results in the
induction of autophagy, relocalization of TDP-43 to its
proper nuclear compartment and reduction of its accu-
mulation, and rescue of mRNA processing51. In addition,
enhancing autophagic flux through an mTOR-
independent pathway with trehalose inhibited TDP-43
aggregate formation52 and autophagy-activating mole-
cules increased TDP-43 clearance and improved neuronal
survival in ALS models53. The positive effect of upregu-
lating autophagy in ALS has been pointed out in SOD1
models54,55. This evidence was also supported by work
using litium salts as autophagy inducers, having a neu-
roprotective effect56. Also, the same authors have shown
that, in glutamate-induced toxicity in MNs, cell death is
associated to impaired autophagy57. Conversely, Zhang
et al.58 found that rapamycin treatment enhances MN
degeneration in a mouse model of ALS. Therefore, to
summarize findings on autophagy and ALS, it seems that
autophagy plays a protective role, even though its induc-
tion is not sufficient to rescue MNs, and several con-
troversial observations are still reported.
Even though ALS and SMA are both MN diseases, and
share some histopathological findings, their etiopatho-
genesis, albeit multifarious, is fundamentally different for
the genes involved and the age of disease onset and
progression.
The effects of autophagy manipulation in SMA are in
partial disagreement to what occurs in ALS, since 3-MA
by blocking autophagy protects MNs. Consequently, our
findings suggested that drugs that induce autophagosome
formation should not be considered for the treatment of
SMA.
Moreover, the repeated administration of 3-MA showed
improved motor performance in SMA pups, thus sug-
gesting that this strategy should be considered for further
studies and analysis. However, chronic use of 3-MA may
Piras et al. Cell Death and Disease  (2017) 8:3223 Page 11 of 16
Official journal of the Cell Death Differentiation Association
have some limitations. This inhibitor reduces autophagy
by its action on class III phosphatidylinositol 3-kinase
(PtdIns3K), but it also affects the class I, which activates
Akt pathway59. Therefore, even though 3-MA represents
an effective inhibitor of autophagy, its therapeutic
potential is limited by virtue of its action on class I
PtdIns3k because, on the contrary, it can equally promote
autophagy especially after long exposure59. Thus, it will be of
interest to investigate the effects of other autophagy inhibi-
tors, e.g. LYR294002 and Wortmannin (reviewed in ref.60).
In summary, in SMA autophagy seems to act more as a
death mechanism (in association with apoptosis, as we
showed) than being neuroprotective. On the other hand,
the distinction between the two roles could be not so
rigid, and the final effect of autophagy could be more
related to its fine tuning than to an all-or-none effect.
To this extent, the tight regulation of autophagy could
be a good strategy to increase the therapeutic potential as
a complementary therapy against SMA, possibly in
combination with the emerging promising treatments
aimed at manipulating the SMN expression (e.g.
nusinersen)61,62.
Materials and methods
In vivo experiments
Animals
Experiments were performed on newborn SMNdelta7
mice (Jackson Laboratories; stock number 005025) from
the animal colony bred in the Neuroscience Institute
Cavalieri Ottolenghi at the University of Turin. Mice were
housed with 12-h light/dark cycle and were given free
access to food and water ad libitum. All animal experi-
mental procedures were in accordance with the European
Communities Council Directive of 24 November 1986
(86/609/EEC), the National Institutes of Health guide-
lines, the Italian law for care and use of experimental
animals (DL116/92), and approved by the Italian Ministry
of Health and the Bioethical Committee of the University
of Turin (authorization number 17/2010-B, 30 June 2010).
Genotyping
The mice were genotyped using DNA isolated from a
small piece of tail. Isolation was performed with protei-
nase k (50 µg) in lysis buffer (10 mM Tris HCl, 50 mM KCl,
0.01% gelatin, 0.45% IGEPAL, 0.4% Tween-20) at 55 °C
overnight under gently shaking. The presence of the
transgene was determined by PCR analysis using primers
that amplify a portion of the smn gene, yielding a 420 bp
product for the wild-type allele and a 150 bp product for
the transgenic one. They were: smn fwd 5′-
TTTTCTCCCTCTTCAGAGTGAT-3′, smn wt rev 5′-
CTGTTTCAAGGGAGTTGTGGC-3′ and smn tg rev 5′-
GGTAACGCCAGGGTTTTCC-3′ as suggested by sup-
pliers (Jackson Laboratories).
Phenotyping
In order to analyze the progression of motor symptoms
in SMA mice model63, we daily checked the body weight
and performed behavioral tests, starting at P2.
(i) Tail suspension test (self-clasping): The pups were
suspended by the tail (15 s) and we evaluated the
hindlimb posture. The score was: 4, normal,
hindlimbs spread open; 3, not completely spread; 2,
often close; 1, always close together; 0, always close
together and in additional postural abnormalities
were present (clasping).
(ii) Righting reflex: We placed the pups on their backs
on a flat surface and we evaluated their ability to
right themselves within 30 s.
(iii) Hindlimb suspension test: The test, developed at
PsychoGenics Inc, evaluated the proximal
hindlimb fatigue, weakness, and muscle strength in
pups. Each animal was given three trials and the
average was recorded. Mice were hanged by their
hindlimbs from the border of standard 50 ml
plastic centrifuge tube filled with a cotton ball
cushion at the bottom. We evaluated the posture
(score). The score was divided into four criteria: 4,
when the pup has a normal hindlimb separation
with tail raised; 3, hindlimbs were closer together
but they rarely touch each other; 2, hindlimbs were
close to each other and usually touching; 1,
weakness apparent and the hindlimbs were almost
always clasping; 0, hindlimbs always were in
clasping.
Stereotaxic surgery and administration of chemical
modulators of autophagy
To manipulate the autophagy pathway, we performed
ICV administration of an autophagy inhibitor, 3-MA (9.8
µg/2 µl, Sigma-Aldrich)64,65 or an inducer, rapamycin (2
ng/2 µL)64,66, in P3 SMA pups. A sham-operated group
was injected with 2 µl of sterile saline (vehicle). Further-
more, another group received 3-MA twice, at P3 and at P6
(D3MA-treated group).
Briefly, neonatal mice were anesthetized by hypothermia
(total duration 3–5min) and their heads were immobilized
on a custom neonatal stereotaxic apparatus at 4 °C during
surgery. 3-MA was injected at stereotaxic coordinates of 0
mm from bregma, 0.8mm lateral to sagittal sinus, and 1.5
mm deep67 with a Hamilton microsyringe. The pups were
then placed on a heat pad, quickly revitalized and subse-
quently returned to their mother.
Tissue processing and immunohistochemical procedures
At postnatal day 9 (P9), the pups were deeply anesthe-
tized and perfused transcardially with 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB), pH 7.4. The lumbar
spinal cord was dissected out, post-fixed in the same
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fixative for 3 h, cryoprotected overnight in 30% sucrose in
0.1 MPB (pH 7.2), embedded in cryostat medium (Killik;
Bio-Optica) and frozen. Sections were cut on the cryostat
at a thickness of 10 µm, mounted onto gelatin-coated
Superfrost® slides, and stored at −20 °C until they were
reacted for immunohistochemistry. For immuno-
fluorescence, the sections were washed in phosphate-
buffered saline (PBS). After immersion in blocking solu-
tion for unspecific binding sites 30 min at room tem-
perature (RT) with 0.3% Triton X-100 and 15% normal
donkey serum (NDS, Sigma-Aldrich) in PBS pH 7.4, the
sections were incubated overnight at 4 °C with the fol-
lowing antibodies:
● rabbit polyclonal anti-LC3 antibody
(anti–Microtubule associated proteins 1A/1B light
chain 3; 1:200, Sigma-Aldrich: catalog # SAB4300571,
Lot# 871521402, a synthetic peptide made around aa.
5–10, according to the protein); LC3 is the only
identified mammalian protein that stably associates
with the autophagosome membranes. Immunoblots
visualized double bands at ~18 kDa (LC3-I) and ~16
kDa (LC3-II), respectively, characteristic of this
protein.
● rabbit poyclonal anti-Beclin 1 antibody (1:200,
AbCAM: catalog # ab16998). Beclin 1 plays a key role
in the recruitment of other AuTophaGy-related
proteins (ATG) involved in the expansion step. In
addition, Beclin 1 can interact with Bcl-2 and Bcl-xL
to regulate both autophagy and apoptosis.
● mouse monoclonal anti-SMI32 antibody (1:1000,
Covance: catalog # SMI-32R). SMI32 visualizes
neuronal cell bodies, dendrites and some thick axons
in the central and peripheral nervous system; it is one
of the most used markers for MN labeling.
● rabbit poyclonal anti-cleaved-caspase-3 antibody
(1:400, Cell Signaling Technology: catalog # 9661,
detects endogenous levels of the large fragment, i.e.
17/19 kDa, of activated caspase-3). Caspase-3 is a
critical executioner of apoptosis, as it is either
partially or completely responsible for the proteolytic
cleavage of many key proteins.
The antibodies were diluted in PBS containing 1.5%
NDS and 0.3% Triton X-100. After rinsing, primary
antibodies were detected by incubating sections for 1 h at
room temperature in 1:100 DyLight 488-conjugated
donkey anti-rabbit or anti-mouse IgG (H+L) and 1:200
cyanine 3-conjugated donkey anti-rabbit or anti-mouse
IgG (H+L) (Jackson Immuno Research Laboratories). The
sections were counterstained with 4′,6′-diamidino-2-phe-
nylindole (DAPI, Sigma-Aldrich, catalog # d9564), rinsed,
coverslipped in 1:1 PB-glycerol, and observed with a
Nikon Eclipse E90i epifluorescence microscope under
appropriate filters and photographed by a Nikon DS-5Mc
digital camera. To create 3D reconstructions, some
preparations were also observed with a Leica TCS SP5
confocal laser scanning microscope (Leica, Mannheim).
To verify the specificity of the secondary antibodies
control sections was reacted similarly, except the primary
antibody was omitted in incubation. No immunolabeling
was seen in control sections (data not shown).
Nissl staining and stereological cell counts
The lumbar spinal cord (P9) was serially cut in 20 μm-
thick sections and every fifth sections were evaluated (100
μm intervals). Section were mounted onto 2% gelatin-
coated Superfrost® slides and air-dried. Slides were
hydrated in distilled water for 1 min and stained with 0.1%
cresyl violet solution for approximately 8 min. The sec-
tions were immersed in ascending alcohols, cleared in
xylene and cover-slipped with Eukitt (Bioptica). After
Nissl staining, the nucleoli of the lower MNs in the ven-
tral horns of the lumbar spinal cord were stereologically
counted at 40×. Only multipolar neurons located in the
ventral somatic columns were counted. A total number of
MNs were obtained with the Optical Fractionator68 by
using a computer-assisted microscope and the Stereo-
Investigator software (MicroBrightField). MNs were
counted on the computer screen using an Optronics
MicroFire digital camera mounted on a Nikon Eclipse
E600 microscope. Ventral gray matter volume of the
reconstructed lumbar spinal cord segments was obtained
using NeuroExplorer software (MicroBrightField). Every
fifth 20 μm-thick Nissl-stained section was reconstructed
at P9. The counting frame size was 75×75 μm and the
sampling grid size 100×100 μm.
TUNEL staining
Cell apoptosis was assessed in the lumbar spinal cord of
pups at P9 by The DeadEnd™ Fluorometric TUNEL
System (Promega, Madison) following the manufacturer’s
instructions. DAPI was employed to stain nuclei.
Electron microscopy
A separate set of animals was killed for electron
microscopy analysis (P5 WT n= 3, P5 SMA n= 3, P10
WT n= 3, P10 SMA n= 3). Pups were anesthetized with
gaseous anesthesia (3% isoflurane vaporized in O2/N2O
50:50) and perfused intracardially with saline solution pH
7.4 followed by fixative (2.5% glutaraldehyde and 2%
paraformaldehyde in PB 0.1 M, pH 7.4). The lumbar spinal
cord (L1−L5) was rapidly dissected and post-fixed over-
night at 4 °C in the same fixative. Samples were then
processed for electron microscopy as previously descri-
bed69. Briefly, samples were postfixed in osmium tetroxide
(1% in PB 0.1 M) for 1 h and contrasted in uranyl acetate
(1% in 70% ethanol) for 20 min. Spinal cords were then
dehydrated in graded alcohols and embedded in Durcar-
pan ACM resin (Fluka, Neu-Ulm). Regions of ventral
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horns were identified and ultrathin sections (from silver
to gold) were cut with an ultramicrotome and a diamond
knife (Diatome). Sections were mounted on formvar-
coated single slot grids. Sections were finally visualized
using a Philips CM100 transmission electron microscope.
Immunoblotting
Animals were killed at P9, spinal cords were dissected
and immediately homogenized in a glass-Teflon Potter
homogenizer in an ice-cold lysis buffer containing 20 mM
Hepes, pH 7.5/10 mM KCl/1.5 mM MgCl2/1 mM ethyle-
nediaminetetraacetic acid/1 mM ethylene glycol tetra-
acetic acid/1 mM DTT/ 0.5% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS)/com-
plete protease inhibitors; Roche Cat. No. 11 697 498 001);
the homogenates were centrifuged at 12,000 rpm for 15
min at 4 °C. Protein concentration was determined using a
Bradford assay (#23236). Proteins extracts (50 µg) were
separated on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (12% polyacrilamide) and
transferred to polyvinylidene difluoride membranes. The
membranes were blocked in 5% nonfat milk in tris-
buffered saline (TBS)-T (200 mM Tris and 1.5 M NaCl with
0.1% Tween 20) and were incubated with primary anti-
body diluted in TBS-T overnight at 4 °C.
The membranes were washed and incubated with sec-
ondary horseradish peroxidase-coupled antibodies (Bio-
Rad Laboratories, goat anti-Mouse IgG #1706516 and
anti-rabbit IgG #1706515) in TBS-T for 1 h at room
temperature. After the final washes, the proteins were
detected by enhanced chemiluminescence. The bands
were quantified using Quantity One® 1-D Analysis Soft-
ware (Bio-Rad Laboratories) and values were normalized
with respect to actin. The values were then expressed as a
percentage relative to the sham level of OD. The anti-
bodies used were as follows: anti-LC3 (L8918) from
Sigma-Aldrich (1:1000), anti-Beclin 1 (Ab62472) from
Abcam (1:800), anti-p62/SQSTM1 (P0067) from Sigma-
Aldrich, anti-β III tubulin (1637) from Millipore (1:400),
goat anti-mouse IgG-HRP (sc-2005) from Santa Cruz
Biotechnology (1:10000) and goat anti-rabbit IgG-HRP
(sc-2004) from Santa Cruz Biotechnology (1:10,000).
In vitro experiments
SMA animals and spinal cord MN isolation and culture
Severe SMA mice FVB.Cg-Tg(SMN2)89AhmbSmn1tm1Msd/J
were kindly provided by Dr. J. Esquerda (IRBLLEIDA-
Universitat de Lleida). Heterozygous animals were crossed
to obtain homozygous Smn−/−;SMN2+/+ (mutSMA).
Littermates mtSMA and Smn+/+;SMN2+/+ (WT) were
used for the experiments. For MNs purification E13
embryos were removed from the uterus and a piece was
snipped from the head for genotyping. The REDExtract-
N-Amp Tissue PCR Kit (Sigma-Aldrich) was used for
genomic DNA extraction and polymerase chain reaction
setup, with the following primers: WT forward 5′-
CTCCGGATATTGGGATTG-3′, SMA reverse 5′-GGTA
ACGCCAGGGTTTTCC-3′ and WT reverse 5’-TTTCTT
CTGGCTGTGCCTTT-3′. After genotyping, MNs from
WT and mutSMA were purified and cultured. Six days
after plating, cells were treated with 5 mM of 3-MA.
Twelve hours later, protein extracts were obtained and
submitted to WB analysis using anti-LC3-II, anti-Smn,
and anti-p62/SQSTM1 antibodies.
WB analysis of cultured MNs
WB analysis was performed as described70. After
treatment cells were rinsed in ice-cold PBS (pH 7.2). Total
cell lysates were collected and resolved in SDS-
polyacrylamide gels and transferred onto polyvinylidene
difluoride Immobilon-P transfer membrane filters (Milli-
pore), using an Amersham Biosciences (Piscataway)
semidry Trans-Blot according to the manufacturer’s
instructions. The membranes were blotted with the spe-
cific antibodies anti-Smn (1:5000) from BD Transduction
Laboratories, anti-p62/SQSTM1 antibody (1:1000), and
anti-LC3 antibody (1:1000) from Cell Signaling Technol-
ogy following the instructions of the providers. Unless
stated otherwise, to control the specific protein content
per lane, membranes were re-probed with a monoclonal
anti-α-Tubulin (Tub) antibody (1:50,000, Sigma-Aldrich),
as described by the provider. Blots were developed using
the Super Signal chemiluminescent substrate (Pierce,
Rockford) or the ECL Advance WB detection kit
(Amersham Biosciences).
Statistical analyses
Survival analysis was performed by Kaplan−Meier
analysis. All the experiments were performed at least
three times and the data were expressed as mean±stan-
dard deviation (SD) or standard error (SEM) of the mean.
Data were analyzed using one-way ANOVA (for the
in vivo results) and Student t-test (for the in vitro results):
p-values< 0.05 were considered significant.
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